Two decades af­ter Gleevec ap­proval, No­var­tis scores new CML OK for 'wild card' STAMP in­hibitor

One of the lat­est ad­di­tions to Vas Narasimhan’s “wild card” drug list has de­liv­ered.

Scem­blix, as as­ci­minib will be mar­ket­ed, will be the first STAMP in­hibitor ap­proved for chron­ic myeloid leukemia, ac­cord­ing to No­var­tis.

More specif­i­cal­ly, the FDA has grant­ed two OKs: an ac­cel­er­at­ed ap­proval for adult pa­tients with Philadel­phia chro­mo­some-pos­i­tive CML in chron­ic phase who were pre­vi­ous­ly treat­ed with two or more ty­ro­sine ki­nase in­hibitors; and full ap­proval for adult pa­tients with Ph+ CML-CP with the T315I mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER